For laboratory research use only - not for human consumption

Hub ยท Peptide Science

Thymosin alpha-1: sequence, TB-500 and published research

Thymosin alpha-1 is a 28-amino-acid peptide first isolated from calf thymus. Its synthetic form is called thymalfasin (Dominari et al., 2020). Thymosin alpha-1 has a different amino acid sequence from full-length thymosin beta-4 and from TB-500, the short fragment of thymosin beta-4 identified by Esposito and colleagues in 2012.

Published 2026-11-19Updated 2026-11-19Written by Form Laboratories research team3 min read

When you see alpha-1 and beta-4 beside the name thymosin, the distinction is in the chains themselves. The letters in an amino acid sequence show which residues make up each chain and in what order. Counting those residues gives the chain length.

This peptide science guide follows the sequence records and a 2020 review of thymosin alpha-1. The guide to what peptides are explains how to read a peptide chain.

  • Guidepeptide science guidePeptide science questions answered from published studies and regulator records: what peptides are, which are approved in Australia and by the FDA, and where research peptides sit.
  • Guidewhat peptides areWhat peptides are: short chains of amino acids made by the body, some approved as medicines. Regulator and study evidence, safety records and Australian legal status. Research material is not a medicine.

Key facts

Key facts for Thymosin alpha-1: sequence, TB-500 and published research
First isolated fromCalf thymus (Goldstein et al., 1977)
Synthetic formThymalfasin (Dominari et al., 2020)
Chain length28 amino acids (Goldstein et al., 1977)
Research topicsT-cell maturation, dendritic-cell signalling and cytokines (Dominari et al., 2020)
Proceedings of the National Academy of Sciences 1977

What is thymosin alpha-1?

Thymosin alpha-1 is a thymic peptide that Goldstein and colleagues first isolated from calf thymus and sequenced in 1977. Their paper reported 28 amino acids and an acetyl group attached at the start of the chain. Amino acid sequences are read from that end, called the N-terminus. Figure 2 of the original paper lists the first five residues as serine, aspartic acid, alanine, alanine and valine, or SDAAV in one-letter notation. The peptide bond guide explains how residues connect along the chain.

  • Guidepeptide bond guideA peptide bond is the amide link that joins two amino acids. How it forms, where it sits, how to count bonds, which foods contain them, and what synthetic peptides and peptide vaccines are.
Proceedings of the National Academy of Sciences 1977 and 1981Drug Testing and Analysis 2012

Is thymosin alpha-1 the same as TB-500 or thymosin beta-4?

Thymosin alpha-1 has its own sequence of 28 amino acids (Goldstein et al., 1977). Thymosin beta-4 has 43 amino acids (Low et al., 1981). Esposito and colleagues identified the seven-residue sequence LKKTETQ with an acetyl group at the start, written Ac-LKKTETQ, in a sample labelled TB-500. Those seven residues come from positions 17 to 23 of thymosin beta-4. The corresponding positions of thymosin alpha-1 read KEKKEVV in Figure 2 of the original sequencing paper. See TB-500 vs thymosin beta-4 for the evidence identifying the fragment.

  • GuideTB-500 vs thymosin beta-4TB-500 and thymosin beta-4 are not the same molecule in the papers that define them: a full-length protein against a short acetylated fragment, compared side by side.
World Journal of Virology 2020

What has published research studied about thymosin alpha-1?

Published research on thymosin alpha-1 has examined how T cells mature, how dendritic cells respond and how immune cells produce signalling proteins called cytokines. Dominari and colleagues covered these topics in their 2020 peer-reviewed review in the World Journal of Virology. The review discusses signalling through Toll-like receptors 2 and 9 in dendritic cells and other myeloid cells. It also describes research on interleukin-2, one of the cytokines discussed in connection with lymphocytes, a group of immune cells that includes T cells.

Therapeutic Goods Administration

Evidence limits

What does the Australian register show for thymalfasin?

The Therapeutic Goods Administration's public Australian Register of Therapeutic Goods search for thymalfasin returned no matching results when checked on 19 November 2026. That result applies to the name searched. The TGA describes the register as a database of therapeutic goods that can be legally supplied in Australia. This article covers peptide identity, published research topics and that public register result. It shows no test result for any Form Laboratories product and gives no preparation or storage steps. Research use only.

Comparison

Chain length and amino acids at positions 17 to 23 of the full peptides. Esposito and colleagues identified that segment of thymosin beta-4 as the acetylated fragment in the TB-500 sample.

Comparison: Thymosin alpha-1: sequence, TB-500 and published research
PeptideChain lengthSequence at positions 17 to 23 or fragment sequenceSource
Thymosin alpha-128 amino acidsKEKKEVVGoldstein et al., 1977, Figure 2
Thymosin beta-443 amino acidsLKKTETQLow et al., 1981 and Esposito et al., 2012
TB-500 fragment7 amino acidsAc-LKKTETQEsposito et al., 2012

FAQ

What is thymosin alpha-1?

Thymosin alpha-1 is a peptide that Goldstein and colleagues sequenced from calf thymus in 1977. Each chain contains 28 amino acid residues.

Is thymosin alpha-1 the same as TB-500?

Thymosin alpha-1 and TB-500 are different peptides. The TB-500 sample analysed by Esposito and colleagues contained an acetylated piece of thymosin beta-4. Its amino acid sequence was LKKTETQ.

What is thymosin alpha-1 studied for?

The 2020 review by Dominari and colleagues discusses research on T-cell development, signalling through receptors in dendritic cells and the production of cytokines.

Citations

4 sources
  1. Dominari A, Hathaway D III, Pandav K, et al. World Journal of Virology. 2020;9(5):67-78 (PMID 33362999).
    doi:10.5501/wjv.v9.i5.67

  2. Goldstein AL, Low TL, McAdoo M, et al. Proceedings of the National Academy of Sciences. 1977;74(2):725-729 (PMID 265536).
    doi:10.1073/pnas.74.2.725

  3. Low TL, Hu SK, Goldstein AL. Proceedings of the National Academy of Sciences. 1981;78(2):1162-1166 (PMID 6940133).
    doi:10.1073/pnas.78.2.1162

  4. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Drug Testing and Analysis. 2012;4(9):733-738 (PMID 22962027).
    doi:10.1002/dta.1402

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease